At a glance
| Field | Details |
|---|---|
| Brand names | Not yet approved |
| Targets | GLP-1R + GCGR |
| Developer | Altimmune |
| Modality | SC injection, once-weekly |
| Approval status | Phase 2 complete, Phase 3 pending |
| Key efficacy | ~15.6% weight loss at 48 weeks (Phase 2 MOMENTUM) |
| Indications | Obesity, MASH |
User Sentiment
Pemvidutide's community is small and primarily clinical trial participants and MASH-focused patient advocates. Obesity trial participants noted strong appetite suppression consistent with the dual-agonist class.
Example(What trial participants report)
IMPACT NASH participants tracking liver outcomes report the combination of weight loss and what appears to be direct liver fat reduction — a distinction they notice in imaging and enzyme markers that improves faster than weight loss alone would predict. The metabolic liver disease community has been watching this specifically.
How it works
GLP-1/glucagon dual with a development strategy that prioritizes MASH alongside obesity. Same mechanistic framework as survodutide: GLP-1R for appetite and insulin, GCGR for energy expenditure and hepatic fat oxidation. Glucagon agonism targets the liver directly — relevant to MASH because the disease is characterized by excessive hepatic fat accumulation and inflammation driven by metabolic dysfunction.
Note(MASH as a registration strategy)
Competing head-to-head with tirzepatide on obesity weight loss is a difficult position — tirzepatide has Phase 3 data, approval, and market share. Competing on MASH is a different game: the indication is distinct, the patient population is different, and the mechanism (direct hepatic fat oxidation via glucagon) gives GLP-1/glucagon drugs a biological argument that GLP-1/GIP drugs can't match. Pemvidutide is explicitly pursuing MASH as its primary registration indication — not a consolation prize, but a deliberate strategy.
Trial data
MOMENTUM (Phase 2, obesity, 48 weeks): ~15.6% weight loss — below survodutide's Phase 2 numbers but within a design not optimized purely for weight loss endpoint.
IMPACT NASH (Phase 2, MASH): Significant hepatic fat reduction and improvement in liver histology scores. Moving toward Phase 3 with MASH as the primary registration indication.
What to Expect
Month 1–3 — GI side effects during escalation, appetite reduction typical of dual-agonist class.
Month 3–6 — 10–12% weight loss range based on MOMENTUM Phase 2 trajectory.
Liver markers — For MASH patients, ALT and AST improvements often visible within 3 months of starting treatment; imaging changes take longer.
Not yet available for prescription — Phase 3 pending. MASH indication is the primary development target.
Dosing and administration
Once-weekly subcutaneous injection. Titration details to be confirmed in Phase 3 [verify].
Development status
| Milestone | Status |
|---|---|
| Phase 2 MOMENTUM (obesity) | Complete — 15.6% at 48 weeks |
| Phase 2 IMPACT NASH | Complete — significant liver improvement |
| Phase 3 initiation | Pending — MASH primary indication |
| FDA filing | ~2028 estimated |
Safety profile
GI profile consistent with GLP-1/glucagon class. Glucagon component managed through titration. No novel safety signals in Phase 2.
Who It's For
- Adults with MASH (metabolic dysfunction-associated steatohepatitis) — particularly those with elevated liver enzymes and confirmed steatosis
- BMI ≥ 30 or ≥ 27 with obesity-related metabolic conditions
- People whose hepatologist is recommending pharmacological intervention for liver disease alongside weight management
Ask your hepatologist specifically about GLP-1/glucagon dual agonists if you've been diagnosed with MASH — this is the mechanism class with the strongest liver-specific data.
Summary(The pemvidutide picture)
Phase 2 weight loss below the dual-agonist GLP-1/GIP range, but MASH is the primary target. If Phase 3 MASH data holds, pemvidutide enters a less crowded indication with a mechanistic advantage — direct hepatic fat oxidation — that pure weight-loss drugs don't provide.